- Location
Amyotrophic Lateral Sclerosis
"-
Nippon Paint Launched Society Care Programs to Embodied The Company's Spirit
Jan 7, 2015Nippon Paint China boosted its Corporate Social Responsibility (CSR) program in 2014, with the launch of its "Society Care" programs in nine big cities around China. These charitable programs drew the participation of over 1,000 voluntary ...
-
LA Fitness Will Host an in-Club Group Fitness Class
Feb 26, 2014In support of Augie's Quest, LA Fitness announced today that it will host an in-club Group Fitness class at more than 500 of the company's locations on February 22, 2014. Augie's Quest is a nonprofit research initiative dedicated to finding ...
Tags: Augie's Quest, LA Fitness, Host in-Club Group Fitness Class
-
Explains Why Some Motor Neurons Are Not Vulnerable to ALS
Jan 23, 2014Explains why some motor neurons are not vulnerable to ALS and points to potential therapeutic target Columbia University Medical Center (CUMC) researchers have identified a gene, called matrix metalloproteinase-9 (MMP-9), that appears to ...
-
There Is No Known Way to Reverse Protein Misfolding
Jan 20, 2014At the heart of brain diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease is protein misfolding, in which distorted proteins are unable to perform their normal functions. At present, there is ...
-
National Institutes of Health Is Teaming up with The NFL on Concussion Research
Dec 26, 2013The U.S. National Institutes of Health is teaming up with the National Football League on research into the long-term effects of repeated head injuries and improving concussion diagnosis. The projects will be supported largely through a ...
Tags: U.S.National Institutes of Health, National Football League
-
ImStar Therapeutics Has Announced The Selection of IMS-088
Nov 29, 2013Canada-based ImStar Therapeutics has announced the selection of IMS-088 as its lead drug candidate for the treatment of amyotrophic lateral sclerosis. IMS-088 is a novel, small-molecule drug that stems from the discovery of a new target ...
-
European Commission Has Granted Orphan Drug Designation to BrainStorm NurOwn
Jul 31, 2013The European Commission has granted orphan drug designation to BrainStorm Cell Therapeutics’ stem cell therapy NurOwn to treat Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease. NurOwn consists of autologous ...
Tags: Orphan Drug, Medicine
-
Rising Pharmaceuticals Is Set to Launch Generic Riluzole Tablets of 50mg Strength
Jun 13, 2013Rising Pharmaceuticals, a finished dosage form generics subsidiary of Aceto, is set to launch generic Riluzole tablets of 50mg strength. The authorized generic version of Covis Pharma's Rilutek is indicated for the treatment of patients ...
Tags: Rising Pharmaceuticals, Tablets
-
ALS-ETF, Denovo Have Entered Into Partnership to Explore Using Denovo's Technology
May 15, 2013The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers (Denovo) have entered into partnership to explore using Denovo's technology to identify potential responder groups for drugs that are being studied in patients suffering from ...
-
Neuralstem Has Obtained Notice of Allowance for a Patent
Apr 8, 2013Neuralstem has obtained notice of allowance for a patent that covers various methods to use expanded spinal cord stem cells such as NSI-566 to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The company completed Phase ...
-
DART Therapeutics Is Developing a Selective Androgen Receptor Modulator Drug Candidate
Mar 21, 2013US-based biotechnology firm DART Therapeutics is developing a selective androgen receptor modulator (SARM) drug candidate for Duchenne muscular dystrophy (DMD). DMD is a pediatric rare disease that affects approximately one in 3,600 boys ...
-
Neuralstem Granted License to Use Its Spinal Cord Delivery Platform and Q Therapeutics
Dec 18, 2012Neuralstem has granted license to use its spinal cord delivery platform and floating cannula to Q Therapeutics. The delivery platform and floating cannula are designed for delivering therapeutic agents to the spinal cord of patients with ...
Tags: Neuralstem, license, delivery platform, floating cannula, Q Therapeutics
